SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

November 03, 2009 07:00 ET

SciClone Pharmaceuticals to Present at Two November Investor Conferences

Merriman Investor Summit on Tuesday, November 10 at 3:20 pm ET; Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17 at 9:25 am ET

FOSTER CITY, CA--(Marketwire - November 3, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences in New York City: Merriman Investor Summit, and Lazard Capital Markets 6th Annual Healthcare Conference. Gary Titus, SciClone's Senior Vice President and Chief Financial Officer, will present a corporate overview and business update at each conference.

WHEN:   Merriman Investor Summit
        Tuesday, November 10; 3:20 pm ET
        New York, NY

WHEN:   Lazard Capital Markets 6th Annual Healthcare Conference
        Tuesday, November 17; 9:25 am ET
        New York, NY

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone

SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in preclinical studies as an enhancer of novel H1N1 flu vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it will seek regulatory approval. For additional information, please visit www.sciclone.com.